Dr. S. Larry Goldenberg was presented with the Doctors of BC Silver Medal of Service award at the Doctors of BC Annual General Meeting on June 6, 2015. Established in 1986, this award confers the Association’s highest honor.
A breakthrough study published in Clinical Cancer Research describes a minimally invasive method for interrogating mechanisms of therapeutic resistance in metastatic castration-resistant prostate cancer.
The Future of Prostate Cancer Care: How Dr. Kim Chi translates research into care is the cover story of the Spring 2015 issue of BC Cancer Foundation's Partners in Discovery Magazine.
Dr. Chi holds the positions of Associate Director, Clinical Research and a Senior Research Scientist at the Vancouver Prostate Centre, and Medical Oncologist, Medical Director - Clinical Trials Unit and Chair - Genitourinary Systemic Group at the BC Cancer Agency.
A recent preliminary retrospective study of patients on active surveillance has demonstrated a technique to enhance the identification of patients requiring definitive treatment.
November 18, 2014 - Prostate Cancer Canada has awarded a third Translation Acceleration Grant under their program TAG2: Novel Therapeutics for Advanced Disease. This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for projects aimed at eliminating advanced disease from affected men.
The latest issue of Vancouver Coastal Health Research Institute News includes a discussion with Dr. Ralph Buttyan on his Prostate Cancer Canada - Movember funded team research program. The article "How Movember’s moustaches are taking prostate cancer down" is available here.
This week, the Canadian Task Force on Preventive Health Care recommended not using PSA as a screening test for prostate cancer.
September 26, 2014 - Prostate Cancer Canada today annouced the results of their funding decision in their Translation Acceleration Grant competition TAG2: Novel Therapeutics for Advanced Disease. This funding is for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer, for projects aimed at eliminating advanced disease from affected men.